Drug Discovery Featured Articles & Applications

1. Measuring Cellular Water Content As A New Tool For Organoid Characterization 9/9/2026

   A collaboration between MIT, KAIST, and Dana Farber Cancer Institute created a technology that, for the first time, quantifies water content in single organoids.

2. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

3. Moving Beyond The mRNA Momentum: The Preclinical Path To Personalized Scalable Solid Tumor Immunotherapies 9/3/2026

   Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.

4. The Future Of Cancer Drug Discovery Is Targeted Immune Activation 9/2/2026

   Using targeted delivery systems to generate therapeutic agents directly within tumors has implications for how oncology drugs are discovered and developed.

5. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

   The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.

6. A Simple Eye Drop For A Blinding Disease? Claris Bio Raises $118M And Prepares For Pivotal Trials 9/1/2026

   CSB-001, Claris Bio’s eye drop for limbal stem cell deficiency, could offer a non-surgical way to improve vision, slow vision loss, and reshape LSCD care.

7. Emerging Fields In Immunology: New Frontiers For Therapeutic Discovery 9/1/2026

   Immunology has expanded into several specialized domains as our understanding of the immune system has grown.

8. Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections 8/27/2026

   Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

9. It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials 8/26/2026

   Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

10. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

    Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.